Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens

UM > Faculty of Health Sciences > DEPARTMENT OF BIOMEDICAL SCIENCES

Status	已發表Published
	Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens
	Chen, W.; Feng, Y.; Gong, R.; Zhu, Z.; Wang, Y.; Zhao, Q.; Dimitrov, D.
	2011-09-15
Source Publication	Journal of virology
ISSN	0022-538X
Pages	9395-9405
Abstract	Soluble forms of the HIV-1 receptor CD4 (sCD4) have been extensively characterized for more than 2 decades as promising inhibitors and components of vaccine immunogens. However, they were mostly based on the first two CD4 domains (D1D2), and numerous attempts to develop functional, high-affinity, stable soluble one-domain sCD4 (D1) have not been successful because of the strong interactions between the two domains. We have hypothesized that combining the power of structure-based design with sequential panning of large D1 mutant libraries against different HIV-1 envelope glycoproteins (Envs) and screening for soluble mutants could not only help solve the fundamental stability problem of isolated D1, but may also allow improvement of D1 affinity while preserving its cross-reactivity. By using this strategy, we identified two stable monomeric D1 mutants, mD1.1 and mD1.2, which were significantly more soluble and bound Env gp120s more strongly (50-fold) than D1D2, neutralized a panel of HIV-1 primary isolates from different clades more potently than D1D2, induced conformational changes in gp120, and sensitized HIV-1 for neutralization by CD4-induced antibodies. mD1.1 and mD1.2 exhibited much lower binding to human blood cell lines than D1D2; moreover, they preserved a β-strand secondary structure and stability against thermally induced unfolding, trypsin digestion, and degradation by human serum. Because of their superior properties, mD1.1 and mD1.2 could be potentially useful as candidate therapeutics, components of vaccine immunogens, and research reagents for exploration of HIV-1 entry and immune responses. Our approach could be applied to other cases where soluble isolated protein domains are needed.
Keyword	CD4 HIV-1 vaccine immunogen
URL	View the original
Language	英語English
The Source to Article	PB_Publication
PUB ID	55340
Document Type	Journal article
Collection	DEPARTMENT OF BIOMEDICAL SCIENCES
Corresponding Author	Dimitrov, D.
Recommended Citation GB/T 7714	Chen, W.,Feng, Y.,Gong, R.,et al. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens[J]. Journal of virology, 2011, 9395-9405.
APA	Chen, W.., Feng, Y.., Gong, R.., Zhu, Z.., Wang, Y.., Zhao, Q.., & Dimitrov, D. (2011). Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. Journal of virology, 9395-9405.
MLA	Chen, W.,et al."Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens".Journal of virology (2011):9395-9405.

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation No.
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh